Debt

3 Months Ended

Mar. 31, 2026

Debt Disclosure [Abstract]

Debt

Debt

The Company’s outstanding debt is shown in the following table (dollars in thousands):

	Maturity Dates	Interest Rates	March 31,		December 31,
			2026		2025
Term loans secured by all assets	12/2026 - 12/2030	3.60 - 9.00%	$	18,840	$	19,578
Term loans secured by property and equipment	09/2026 - 01/2030	3.41 - 7.82%	5,318		5,813
Line of credit secured by all assets	09/2026	6.75%	146		740
Term loans of Real Estate VIEs	05/2028 - 03/2037	3.50 - 3.59%	10,242		10,563
Seller note	09/2035	8.00%	5,800		5,800
Deferred payment	09/2035	10.00%	1,000		1,000
Total			41,346		43,494
Less: unamortized issuance costs and discount			211		244
Less: short-term lines of credit			146		740
Less: current portion of long-term debt			16,728		13,336
Total long-term debt			$	24,261	$	29,174

Term loans and lines of credit. We have entered into private debt arrangements with banking institutions for the purchase of equipment and to provide working capital and liquidity through cash and lines of credit. Unless otherwise delineated above, these debt arrangements are obligations of Nutex and/or its wholly-owned subsidiaries. Consolidated real estate entities have entered into private debt arrangements with banking institutions for purposes of purchasing land, constructing new emergency room facilities and building out leasehold improvements which are leased to our hospital entities. Nutex is a guarantor or, in limited cases, a co-borrower on the debt arrangements of the Real Estate VIEs for the periods shown.

Certain outstanding debt arrangements require minimum debt service coverage ratios and other financial covenants. At March 31, 2026, we were in compliance with these debt arrangements; we had remaining availability of $3.4 million under outstanding lines of credit.

There have been no significant changes to the terms of the Company's debt and covenants from those disclosed in Note 8 to the financial statements presented in the 2025 Form 10-K.